Full text loading...
Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation
1.R. Mohan, C. Chui, and L. Lidofsky, “Differential pencil beam dose computation model for photons,” Med. Phys. 13, 64–73 (1986).
2.A. Ahnesjo, P. Andreo, and A. Brahme, “Calculation and application of point spread functions for treatment planning with high energy photon beams,” Acta Oncol. 26, 49–56 (1987).
3.A. Boyer and E. Mok, “A photon dose distribution model employing convolution calculations,” Med. Phys. 12, 169–177 (1985).
4.P. J. Keall and P. W. Hoban, “Superposition dose calculation incorporating Monte Carlo generated electron track kernels,” Med. Phys. 23, 479–485 (1996).
5.C. M. Ma, E. Mok, A. Kapur, T. Pawlicki, D. Findley, S. Brain, K. Forster, and A. L. Boyer, “Clinical implementation of a Monte Carlo treatment planning system,” Med. Phys. 26, 2133–2143 (1999).
6.T. R. Mackie, J. W. Scrimger, and J. J. Battista, “A convolution method of calculating dose for 15-MV x rays,” Med. Phys. 12, 188–196 (1985).
7.T. Bortfeld, A. L. Boyer, W. Schlegel, D. L. Kahler, and T. J. Waldron, “Realization and verification of three-dimensional conformal radiotherapy with modulated fields [see comments],” Int. J. Radiat. Oncol., Biol., Phys. 30, 899–908 (1994).
8.D. J. Convery and M. E. Rosenbloom, “Treatment delivery accuracy in intensity-modulated conformal radiotherapy,” Phys. Med. Biol. 40, 979–999 (1995).
9.J. Stein, T. Bortfeld, B. Dorschel, and W. Schlegel, “Dynamic x-ray compensation for conformal radiotherapy by means of multileaf collimation,” Radiother. Oncol. 32, 163–173 (1994).
10.L. J. Verhey, “Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems,” Geriatr. Nephrol. Urol. 9, 78–98 (1999).
11.T. R. Mackie, T. Holmes, S. Swerdloff, P. Reckwerdt, J. O. Deasy, J. Yang, B. Paliwal, and T. Kinsella, “Tomotherapy: A new concept for the delivery of dynamic conformal radiotherapy,” Med. Phys. 20, 1709–1719 (1993).
12.G. M. Cattaneo, G. Rizzo, P. Lombardi, G. Ceresoli, A. Savi, M. C. Gilardi, E. Villa, and R. Calandrino, “[Integration of computerized tomography imaging with single photon emission in a commercial system for developing radiotherapy fields: Application to conformational irradiation for lung carcinoma],” Radiol. Med. (Torino) 97, 272–278 (1999).
13.G. T. Chen, C. A. Pelizzari, and D. N. Levin, “Image correlation in oncology,” Important Adv. Oncol., edited by V. T. Devita, S. Hellman, and S. A. Rosenberg (Lippincott Williams & Wilkins, Philadelphia, 1990), pp. 131–141.
14.R. Day, M. P. Heilbrun, S. Koehler, P. McDonald, W. Peters, and V. Siemionow, “Three-point transformation for integration of multiple coordinate systems: Applications to tumor, functional, and fractionated radiosurgery stereotactic planning,” Stereotact Funct Neurosurg. 63, 76–79 (1994).
15.S. Dymarkowski, S. Sunaert, S. Van Oostende, P. Van Hecke, G. Wilms, P. Demaerel, B. Nuttin, C. Plets, and G. Marchal, “Functional MRI of the brain: Localization of eloquent cortex in focal brain lesion therapy,” Eur. Radiol. 8, 1573–1580 (1998).
16.R. J. Hamilton, P. J. Sweeney, C. A. Pelizzari, F. Z. Yetkin, B. L. Holman, B. Garada, R. R. Weichselbaum, and G. T. Chen, “Functional imaging in treatment planning of brain lesions,” Int. J. Radiat. Oncol., Biol., Phys. 37, 181–188 (1997).
17.C. C. Ling, J. Humm, S. Larson, H. Amols, Z. Fuks, S. Leibel, and J. A. Koutcher, “Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality [see comments],” Int. J. Radiat. Oncol., Biol., Phys. 47, 551–560 (2000).
18.Y. Lu, D. R. Spelbring, and G. T. Chen, “Functional dose-volume histograms for functionally heterogeneous normal organs,” Phys. Med. Biol. 42, 345–356 (1997).
19.L. B. Marks, D. P. Spencer, G. W. Sherouse, G. Bentel, R. Clough, K. Vann, R. Jaszczak, R. E. Coleman, and L. R. Prosnitz, “The role of three-dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram,” Int. J. Radiat. Oncol., Biol., Phys. 33, 65–75 (1995).
20.L. B. Marks, M. T. Munley, G. C. Bentel, S. M. Zhou, D. Hollis, C. Scarfone, G. S. Sibley, F. M. Kong, R. Jirtle, R. Jaszczak, R. E. Coleman, V. Tapson, and M. Anscher, “Physical and biological predictors of changes in whole-lung function following thoracic irradiation [see comments],” Int. J. Radiat. Oncol., Biol., Phys. 39, 563–570 (1997).
21.L. B. Marks, G. W. Sherouse, M. T. Munley, G. C. Bentel, and D. P. Spencer, “Incorporation of functional status into dose-volume analysis,” Med. Phys. 26, 196–199 (1999).
22.M. T. Munley, L. B. Marks, C. Scarfone, G. S. Sibley, E. F. Patz, Jr., T. G. Turkington, R. J. Jaszczak, D. R. Gilland, M. S. Anscher, and R. E. Coleman, “Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects,” Lung Cancer 23, 105–114 (1999).
23.J. Nuutinen, P. Sonninen, P. Lehikoinen, E. Sutinen, R. Valavaara, E. Eronen, S. Norrgard, J. Kulmala, M. Teras, and H. Minn, “Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma,” Int. J. Radiat. Oncol., Biol., Phys. 48, 43–52 (2000).
24.F. S. Pardo et al., “Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma,” Int. J. Radiat. Oncol., Biol., Phys. 30, 663–669 (1994).
25.C. Scarfone, R. J. Jaszczak, D. R. Gilland, K. L. Greer, M. T. Munley, L. B. Marks, and R. E. Coleman, “Quantitative pulmonary single photon emission computed tomography for radiotherapy applications,” Med. Phys. 26, 1579–1588 (1999).
26.M. Schulder, J. Vega, V. Narra, A. Jacobs, A. Kalnin, G. Lange, and W. C. Liu, “Functional magnetic resonance imaging and radiosurgical dose planning,” Stereotact Funct Neurosurg. 73, 38–44 (1999).
27.A. Niemierko, “Reporting and analyzing dose distributions: A concept of equivalent uniform dose [see comments],” Med. Phys. 24, 103–110 (1997).
28.A. Niemierko, “A generalized concept of equivalent uniform dose (EUD),” Med. Phys. 26, 1100 (1999).
29.IAEA, Radiation dose in radiotherapy from perscription to delivery, Leuven, 1994.
30.ICRU, Report 50. Prescribing, recording, and reporting photon beam therapy, Washington, D.C., 1993.
31.A. Brahme, “Dosimetric precision requirements in radiation therapy,” Acta Radiol. Oncol. 23, 379–391 (1984).
32.J. F. Fowler, “The linear-quadratic formula and progress in fractionated radiotherapy,” Br. J. Radiol. 62, 679–694 (1989).
33.E. J. Hall, Radiobiology for the Radiologist, 4th ed. (J. B. Lippincott, Philadelphia, 1994).
34.Gustav Konrad Von Schulthess, Clinical Positron Emission Tomography (Pet): Correlation with Morphological Cross-Sectional Imaging (Lippincott Williams and Wilkins, Philadelphia, 2000).
35.A. Al-Sugair and R. E. Coleman, “Applications of PET in lung cancer,” Semin Nucl. Med. 28, 303–319 (1998).
36.K. Kubota, S. Yamada, T. Kondo, K. Yamada, H. Fukuda, T. Fujiwara, M. Ito, and T. Ido, “PET imaging of primary mediastinal tumours,” Br. J. Cancer 73, 882–886 (1996).
37.C. Schiepers, “Role of positron emission tomography in the staging of lung cancer,” Lung Cancer 17, Suppl. 1, S29–S35 (1997).
38.N. A. Dewan, N. C. Gupta, L. S. Redepenning, J. J. Phalen, and M. P. Frick, “Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: Potential role in evaluation and management,” Chest 104, 997–1002 (1993).
39.M. Lonneux, D. Delval, R. Bausart, R. Moens, R. Willockx, P. Van Mael, P. Declerck, F. Jamar, H. Zreik, and S. Pauwels, “Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer,” Nucl. Med. Commun. 19, 1047–1054 (1998).
40.M. Lonneux, M. Sibomana, S. Pauwels, and V. Gregoire, “[Current data and perspectives on positron emission tomography oncology-radiotherapy],” Cancer Radiother 3, 275–288 (1999).
41.U. Nestle, K. Walter, S. Schmidt, N. Licht, C. Nieder, B. Motaref, D. Hellwig, M. Niewald, D. Ukena, C. M. Kirsch, G. W. Sybrecht, and K. Schnabel, “18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis,” Int. J. Radiat. Oncol., Biol., Phys. 44, 593–597 (1999).
42.E. F. Patz, Jr., V. J. Lowe, P. C. Goodman, and J. Herndon, “Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma,” Chest 108, 1617–1621 (1995).
43.R. S. Brown, J. Y. Leung, S. J. Fisher, K. A. Frey, S. P. Ethier, and R. L. Wahl, “Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important?,” J. Nucl. Med. 36, 1854–1861 (1995).
44.H. Minn, H. Joensuu, A. Ahonen, and P. Klemi, “Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors,” Cancer 61, 1776–1781 (1988).
45.M. Sasaki, Y. Ichiya, Y. Kuwabara, Y. Akashi, T. Yoshida, T. Fukumura, S. Murayama, T. Ishida, K. Sugio, and K. Masuda, “The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with nonsmall cell lung cancer: A comparative study with x-ray computed tomography,” Eur. J. Nucl. Med. 23, 741–747 (1996).
46.T. Bury, A. Barreto, F. Daenen, N. Barthelemy, B. Ghaye, and P. Rigo, “Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with nonsmall cell lung cancer,” Eur. J. Nucl. Med. 25, 1244–1247 (1998).
47.A. L. Folpe, R. H. Lyles, J. T. Sprouse, E. U. Conrad , 3rd, and J. F. Eary, “(F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma,” Clin. Cancer Res. 6, 1279–1287 (2000).
48.K. L. Berger, S. A. Nicholson, F. Dehdashti, and B. A. Siegel, “FDG PET evaluation of mucinous neoplasms: Correlation of FDG uptake with histopathologic features,” AJR, Am. J. Roentgenol. 174, 1005–1008 (2000).
49.T. Higashi, N. Tamaki, T. Torizuka, Y. Nakamoto, H. Sakahara, T. Kimura, T. Honda, T. Inokuma, S. Katsushima, G. Ohshio, M. Imamura, and J. Konishi, “FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors,” J. Nucl. Med. 39, 1727–1735 (1998).
50.K. Ito, T. Kato, T. Ohta, M. Tadokoro, T. Yamada, M. Ikeda, M. Nishino, T. Ishigaki, and S. Gambhir, “Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: Relation to tumour size and cellularity,” Eur. J. Nucl. Med. 23, 1372–1377 (1996).
51.B. Lippitz, U. Cremerius, L. Mayfrank, H. Bertalanffy, R. Raoofi, J. Weis, A. Bocking, U. Bull, and J. M. Gilsbach, “PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate,” Acta Neurochir. Suppl. (Wien) 65, 108–111 (1996).
52.U. Tateishi, H. Nishihara, E. Tsukamoto, T. Morikawa, N. Tamaki, and K. Miyasaka, “Lung tumors evaluated with FDG-PET and dynamic CT: The relationship between vascular density and glucose metabolism,” J. Comput. Assist. Tomogr. 26, 185–190 (2002).
53.R. Bos, J. J. van Der Hoeven, E. van Der Wall, P. van Der Groep, P. J. van Diest, E. F. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, and C. F. Molthoff, “Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography,” J. Clin. Oncol. 20, 379–387 (2002).
54.H. Uehara, T. Miyagawa, J. Tjuvajev, R. Joshi, B. Beattie, T. Oku, R. Finn, and R. Blasberg, “Imaging experimental brain tumors with 1-aminocyclopentane carboxylic acid and alpha-aminoisobutyric acid: Comparison to fluorodeoxyglucose and diethylenetriaminepentaacetic acid in morphologically defined tumor regions,” J. Cereb. Blood Flow Metab. 17, 1239–1253 (1997).
55.K. Herholz, U. Pietrzyk, J. Voges, R. Schroder, M. Halber, H. Treuer, V. Sturm, and W. D. Heiss, “Correlation of glucose consumption and tumor cell density in astrocytomas: A stereotactic PET study,” J. Neurosurg. 79, 853–858 (1993).
56.Y. Kitagawa, K. Sano, S. Nishizawa, M. Nakamura, T. Ogasawara, N. Sadato, and Y. Yonekura, “FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer,” Eur. J. Nucl. Med. 30, 63–71 (2003).
57.A. Buck, H. Schirrmeister, T. Kuhn, C. Shen, T. Kalker, J. Kotzerke, A. Dankerl, G. Glatting, S. Reske, and T. Mattfeldt, “FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters,” Eur. J. Nucl. Med. 29, 1317–1323 (2002).
58.C. Reisser, U. Haberkorn, and L. G. Strauss, “The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors,” J. Otolaryngol. 22, 231–238 (1993).
59.J. Okada, K. Yoshikawa, M. Itami, K. Imaseki, K. Uno, J. Itami, J. Kuyama, A. Mikata, and N. Arimizu, “Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity,” J. Nucl. Med. 33, 325–329 (1992).
60.J. Okada, K. Yoshikawa, K. Imazeki, S. Minoshima, K. Uno, J. Itami, J. Kuyama, H. Maruno, and N. Arimizu, “The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis,” J. Nucl. Med. 32, 686–691 (1991).
61.H. Minn, M. Lapela, P. J. Klemi, R. Grenman, S. Leskinen, P. Lindholm, J. Bergman, E. Eronen, M. Haaparanta, and H. Joensuu, “Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer,” J. Nucl. Med. 38, 1907–1911 (1997).
62.M. Utriainen, L. Metsahonkala, T. T. Salmi, T. Utriainen, H. Kalimo, H. Pihko, A. Makipernaa, A. Harila-Saari, S. Jyrkkio, J. Laine, K. Nagren, and H. Minn, “Metabolic characterization of childhood brain tumors: Comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography,” Cancer 95, 1376–1386 (2002).
63.N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Janicke, W. Nathrath, and M. Schwaiger, “Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis,” J. Nucl. Med. 42, 9–16 (2001).
64.P. T. Meyer, U. Spetzger, H. D. Mueller, T. Zeggel, O. Sabri, and M. Schreckenberger, “High F-18 FDG uptake in a low-grade supratentorial ganglioma: a positron emission tomography case report,” Clin. Nucl. Med. 25, 694–697 (2000).
65.K. Higashi, Y. Ueda, M. Yagishita, Y. Arisaka, A. Sakurai, M. Oguchi, H. Seki, Y. Nambu, H. Tonami, and I. Yamamoto, “FDG PET measurement of the proliferative potential of non-small cell lung cancer,” J. Nucl. Med. 41, 85–92 (2000).
66.T. R. DeGrado, T. G. Turkington, J. J. Williams, C. W. Stearns, J. M. Hoffman, and R. E. Coleman, “Performance characteristics of a whole-body PET scanner,” J. Nucl. Med. 35, 1398–1406 (1994).
67.J. G. Rosenman, E. P. Miller, G. Tracton, and T. J. Cullip, “Image registration: An essential part of radiation therapy treatment planning,” Int. J. Radiat. Oncol., Biol., Phys. 40, 197–205 (1998).
68.V. J. Lowe and K. S. Naunheim, “Current role of positron emission tomography in thoracic oncology,” Thorax 53, 703–712 (1998).
69.W. A. Weber, M. Schwaiger, and N. Avril, “Quantitative assessment of tumor metabolism using FDG-PET imaging,” Nucl. Med. Biol. 27, 683–687 (2000).
70.M. M. Graham, L. M. Peterson, and R. M. Hayward, “Comparison of simplified quantitative analyses of FDG uptake,” Nucl. Med. Biol. 27, 647–655 (2000).
71.W. C. Eckelman, J. L. Tatum, K. A. Kurdziel, and B. Y. Croft, “Quantitative analysis of tumor biochemistry using PET and SPECT,” Nucl. Med. Biol. 27, 633–635 (2000).
72.F. G. Duhaylongsod, V. J. Lowe, E. F. Patz, Jr., A. L. Vaughn, R. E. Coleman, and W. G. Wolfe, “Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography,” Ann. Thorac. Surg. 60, 1348–1352 (1995).
73.H. Minn, A. C. Clavo, R. Grenman, and R. L. Wahl, “In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck,” J. Nucl. Med. 36, 252–258 (1995).
74.V. Ahuja, R. E. Coleman, J. Herndon, and E. F. Patz, Jr., “The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma,” Cancer 83, 918–924 (1998).
75.J. F. Vansteenkiste, S. G. Stroobants, P. J. Dupont, P. R. De Leyn, E. K. Verbeken, G. J. Deneffe, L. A. Mortelmans, and M. G. Demedts, “Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group,” J. Clin. Oncol. 17, 3201–3206 (1999).
76.A. Terahara, A. Niemierko, M. Goitein, D. Finkelstein, E. Hug, N. Liebsch, D. O’Farrell, S. Lyons, and J. Munzenrider, “Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma,” Int. J. Radiat. Oncol., Biol., Phys. 45, 351–358 (1999).
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Article metrics loading...